Phase II study of neoadjuvant and adjuvant docetaxel/cisplatin/5-fluorouracil in resectable esophagus cancer - Phase II study of neoadjuvant and adjuvant docetaxel/cisplatin/5-fluorouracil in resectable esophagus cancer

Jikei university of medicine department of surgery, department of oncology and hematology0 个研究点目标入组 12 人开始时间: 2011年5月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Known hypersensitivity to taxanes, platinum, fluoropyrimidines. Known dihydropyrimidine-dehydrogenase (DPD) deficit. (2) Pre-existing motor or sensory neurotoxicity of a severity => Grade2 (CTCAE v4.0) (3) Active infectious diseases. (4) Symptomatic bleeding tendency, coagulation disorder, or coagulation factor deficiency. (5) Uncontrollable hypertension, uncontrollable diabetes, unstable angina, or heart failure. (6) Pre-existing renal insufficiency or proteinuria => 2+. (7) Clinical or radiographic signs of interstitial pneumonia or pulmonary fibrosis. (8) Active gastrointestinal bleeding, bowel obstruction. (9) Severe mental disorders, neurological disease (10) Pregnant or lactation women, or women with the possibility of the pregnancy. (11) Men who want let to pregnancy. (12) Patients who are judged inappropriate for the entry into this study by the investigator. (13) Active synchronous or metachronous malignancy, excepting for early stage cancers of the oral cavity, pharynx, larynx and early (stage Ia) gastric cancer.

发起方

Jikei university of medicine department of surgery, department of oncology and hematology